Active Ingredient(s): Pexidartinib Hydrochloride
FDA Approved: * August 2, 2019

* This drug may consist of multiple approval dates, manufacturers, or distributors. If applicable, they would be listed below under "NDC Database Records".

Turalio Overview

Pexidartinib, sold under the brand name Turalio, is a kinase inhibitor drug for the treatment of adults with symptomatic tenosynovial giant cell tumor (TGCT) associated with severe morbidity or functional limitations and not amenable to improvement with surgery. Pexidartinib blocks the activity of the colony-stimulating factor-1 receptor (CSF-1R). [1][2][3][4] Common side effects are increased lactate dehydrogenase (proteins tha...

Read more Turalio Details
Details May Include Instructions, Side Effects, Interactions, Etc. Drug monograph is from Wikipedia. All text is available under the terms of the GFDL (GNU Free Documentation License). Source: en.wikipedia.org/wiki/Pexidartinib

Recent Turalio Forums:

Be the first to start a discussion about this drug.

Possible Dosages for this and Related Drugs:

Pexidartinib Hydrochloride
  • Capsule: 200mg
Note: Above list includes dosages for all drugs with the same combination of active ingredients.

NDC Database Records for Turalio: (1 result)

Sorted by National Drug Code
  • 65597-402 Turalio 200 mg Oral Capsule by Daiichi Sankyo Inc.

Other drugs which contain Pexidartinib Hydrochloride or a similar ingredient: (1 result)